Tissue Factor Inhibitors
1 drugsAbout Tissue Factor
Tissue Factor (TF), or coagulation factor III, is a transmembrane protein initiating blood coagulation upon vascular injury. While essential for hemostasis, aberrant TF expression is implicated in disease, particularly in oncology.
Tissue Factor is a compelling oncology target due to its role in tumor angiogenesis and metastasis. Currently, there is no genetic evidence data available linking Tissue Factor to specific diseases.
Tissue Factor is targeted by one FDA-approved drug, TIVDAK, an antibody-drug conjugate (ADC). SEAGEN is the sole company with an approved drug for this target in oncology.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Colorectal Neoplasms with only 1 trials.
Top Tissue Factor Drugs
SEAGEN is the only company with an approved Tissue Factor-targeting drug.
The market is highly concentrated, indicating potential entry barriers or limited investment in this target.
Tissue Factor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Tissue Factor, using adc modality.
The lack of modality diversity suggests an opportunity for novel therapeutic approaches beyond ADCs.
Tissue Factor Clinical Trials 12 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 4 | 1 | 0 | 80% |
| Phase 2 | 4 | 3 | 0 | 1 | 100% |
| Phase 3 | 2 | 1 | 0 | 1 | 100% |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Tissue Factor Drug Approval Timeline (2021 - 2021)
The first and most recent drug approval for Tissue Factor was TIVDAK in 2021.
Recent entry suggests renewed interest, but single approval indicates potential saturation or high development hurdles.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 20 clinical trials targeting Tissue Factor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities